SAN FRANCISCO and BOSTON, March  26, 2026  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class

APGE

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

Apogee Therapeutics Raises $403 Million in Public Offering

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>SAN FRANCISCO and BOSTON, March  26, 2026  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Apogee Therapeutics has closed a successful public offering of 5.75 million shares at $70.00 each, raising about $403 million. This capital will support the advancement of their novel biologics aimed at treating inflammatory and immunology conditions, potentially enhancing their market position significantly.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Apogee closed a public offering of 5.75 million shares.</li><li>Shares were priced at $70.00, raising approximately $403 million.</li><li>Funds from the offering will enhance development of their I&amp;I drug pipeline.</li><li>The company focuses on under-served markets like asthma and dermatitis.</li><li>APGE aims for best-in-class healthcare solutions with novel biologics.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Jefferies (JEF)</strong>: Acted as a joint book-running manager for the offering.</li><li><strong>TD Cowen (TD)</strong>: Involved as a joint book-running manager in the offering.</li><li><strong>Stifel (SF)</strong>: Participated as a joint book-running manager in Apogee&#039;s offering.</li><li><strong>Guggenheim Securities (GUG)</strong>: Also acted as a joint book-running manager for the offering.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>This announcement falls under corporate developments, particularly regarding capital raising activities which are critical for a clinical-stage biotech&#039;s operational runway and future innovations.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>The $403 million raised will be pivotal for funding Apogee&#039;s drug development.</li><li>Potential market expansion in under-penetrated I&amp;I therapeutic areas may enhance revenue.</li><li>Positive investor sentiment around the public offering could bolster share prices.</li><li>Success in clinical trials may lead to higher valuations.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>5.75 million shares offered, including 750,000 from underwriters&#039; options.</li><li>Offer price was set at $70.00 per share.</li><li>Total gross proceeds from the offering: $403 million.</li><li>Offering enhances funding for Apogee&#039;s lead program, Zumilokibart (APG777).</li><li>SEC filing date of the registration statement: August 12, 2024.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Consider a bullish position on APGE, expecting price appreciation post-raise within 6 months.</p>
  </section>
</section>


<link type="text/css" rel="stylesheet" href="https://www.globenewswire.com/styles/gnw_nitf.css"></link><p align="justify">SAN FRANCISCO and BOSTON, March  26, 2026  (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/APGE">APGE</a>), a clinical-stage biotechnology company advancing optimized, novel biologics with the potential for best-in-class profiles in the largest inflammatory and immunology (I&amp;I) markets, today announced the closing of its previously announced underwritten public offering of 5,750,000 shares of its common stock, including the full exercise of the underwriters' option to purchase up to 750,000 additional shares, at a public offering price per share of $70.00. The aggregate gross proceeds to Apogee from the offering were approximately $403 million before deducting underwriting discounts and commissions and other offering expenses payable by Apogee.</p>  <p align="justify">Jefferies, TD Cowen, Stifel and Guggenheim Securities acted as joint book-running managers for the offering. Wedbush PacGrow and BTIG acted as lead managers for the offering.</p>  <p align="justify">An automatically effective shelf registration statement relating to these securities was filed with the Securities and Exchange Commission (SEC) on August 12, 2024. This offering was made only by means of a written prospectus, including a prospectus supplement, forming a part of an effective registration statement. A copy of the final prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC, are available on the SEC's website at <a href="http://www.sec.gov" title="www.sec.gov">www.sec.gov</a> and may be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Stifel, Nicolaus &amp; Company, Incorporated, Attention: Syndicate, One Montgomery Street, Suite 3700, San Francisco, CA 94104, by telephone at (415) 364-2720 or by email at syndprospectus@stifel.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at <a href="mailto:GSEquityProspectusDelivery@guggenheimpartners.com">GSEquityProspectusDelivery@guggenheimpartners.com</a>.</p>  <p align="justify">This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</p>  <p align="justify"><strong>About Apogee</strong></p>  <p align="justify">Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the largest I&amp;I markets, including for the treatment of Atopic Dermatitis (AD), asthma, Eosinophilic Esophagitis (EoE), Chronic Obstructive Pulmonary Disease (COPD) and other I&amp;I indications. Apogee's antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of action and incorporating advanced antibody engineering to optimize half-life and other properties. Zumilokibart (APG777), the Company's most advanced program, is being initially developed for the treatment of AD, which is the largest and one of the least penetrated I&amp;I markets, as well as asthma and EoE. With four validated targets in its portfolio, Apogee is seeking to achieve best-in-class efficacy and dosing through monotherapies and combinations of its novel antibodies. Based on a broad pipeline and depth of expertise, the Company believes it can deliver value and meaningful benefit to patients underserved by today's standard of care.</p>  <p align="justify"><strong>Investor Contact:</strong><br></br>Noel Kurdi<br></br>VP, Investor Relations<br></br>Apogee Therapeutics, Inc.<br></br>Noel.Kurdi@apogeetherapeutics.com</p>  <p align="justify"><strong>Media Contact:</strong><br></br>Dan Budwick<br></br>1AB Media<br></br>dan@1abmedia.com</p> <img alt="" class="__GNW8366DE3E__IMG" src="https://www.globenewswire.com/newsroom/ti?nf=OTY3OTM0NiM3NTA1OTM4IzIyNTkyMjc="></img> <br></br><img alt="" src="https://ml.globenewswire.com/media/ZjhlNzQ5Y2EtMzdiYS00MjZhLThkMzUtZmI4MDRkZGJkYzc5LTEyNzA3NzctMjAyNi0wMy0yNi1lbg==/tiny/Apogee-Therapeutics.png" referrerpolicy="no-referrer-when-downgrade"></img><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b"><img src="https://ml.globenewswire.com/media/c7ab4c17-2e41-4560-b2a2-70d0c23c8c8b/small/apogeelogo-png.png" border="0" width="150" height="42" alt="Primary Logo"></img></a></p>

Apogee Therapeutics has closed a successful public offering of 5.75 million shares at $70.00 each, raising about $403 million. This capital will support the advancement of their novel biologics aimed at treating inflammatory and immunology conditions, potentially enhancing their market position significantly.

apogee-therapeutics-inc-announces-closing-of-public-offering-and-full-exercise-of-the-underwriters-option-to-purchase-additional-shares-for-gross-proceeds-of-403-million

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $403 Million

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News